natgillin/translations-raw huggingface dataset:
Particularly in the case of a not so frequent use of the machine, when beverages with a certain content of fatty substances (e.g. coffee and meat stock or consommé) are prepared, there exists a real risk for these substances to eventually ferment and grow rancid in the conduits, and this is certainly a development that people due to drink the beverages flowing out of said conduits are quite likely to find rather unpleasant. 
U slučaju neredovite upotrebe stroja, oosbito kada se pripravlja napitke s izvjesnom količinom masnih tvari (primjerice kavu i bujon ili bistru juhu), postoji stvaran rizik da te tvari s vremenom fermentiraju i da se užegnu u cjevovodima, što je svakako Tazlog zbog kojeg su ljudima koji piju napitke koji istječu iz navedenih cjevovoda ti napici vrlo vjerojatno prilično neugodni.
the vector according to claim 6;or 
vektor prema zahtjevu 20; ili
at each occurrence, is independently selected from: halogen, C1-4 haloalkyl, and C1-6 alkoxy; and R6, at each occurrence, is independently selected from: halogen, C1-6 alkyl, C1-4 alkoxy, C3-6 cycloalkyl substituted with 0-2 C1-4 alkyl, and C5-6 cycloalkenyl substituted with 0-2 C1-4 alkyl. 
R* u svakom slučaju, je nezavisno odabran od: halogena, C;.4 haloalkila, i C1.4 alkoksi; i R*, u svakom slučaju, je nezavisno odabran od: halogena, C1g alkila, C,4 alkoksi, C34 cikloalkila supstituiranog 0-2 C,.4 alkilom, i Cs4 cikloalkenila supstituiranog 0-2 C,.4 alkilom.
The compound according to claim 1 or claim 2, wherein the salt is selected from hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, p -toluenesulfonate; sodium, potassium, calcium, ammonium salts; and ethylenediamine, ethanolamine, N, N -dialkylenethanolamine, triethanolamine and basic aminoacids salts. 
PATENTNI ZAHTJEVI VI. Sjedinjenje u skladu sa patentnim zahtjevom 1 ili patentnim zahtjevom 2, gdje je sol odabrana od hidroklorid, hidrobromid, hidrojodid, sulfat, nitrat, fosfat, acetat, trifluoroacetat, maleat, fumarat, citrat, oksalat, sukcinat, tartarat, malat, mandelat, metansulfonat, p-toluensulfonat; natrij, kalij, kalcij, amonij soli; i soli etilendiamina, etanolamina, N,N-dial kilen etanolamina, trietanolamina i baznih aminokiselina.
orientable solar collectors maintained a distance away from crops in a ground by the bearing structure; 
orijentirajuće solarne kolektore (10) koji se drže na udaljenosti od tla pomoću nosive konstrukcije (20),
The agent may be introduced into the silk fibroin solution before, during, or after the ultrasonication treatment. The agent can represent any material capable of being encapsulated in the silk fibroin gel. For example, the agent may be a therapeutic agent, such as small molecules and drugs, or a biological material, such as cells (including stem cells), proteins, peptides, nucleic acids (DNA, RNA, siRNA), PNA, aptamers, antibodies, hormones, growth factors, cytokines, or enzymes. 
Postupak prema zahtjevu 11 ili 12, gdje je sredstvo terapijsko sredstvo ili biološki materijal, ili oboje, i/ili gdje je sredstvo barem jedan biološki materijal izabran iz skupine koja obuhvaća stanice, proteine, peptide, nukleinske kiseline, PNA, aptamere, protutijela, hormone, faktore rasta, citokine, enzime, antimikrobne spojeve i njihove kombinacije, i/ili gdje je stanica ne-embrionska matična stanica, i/ili gdje se medij za stanični rast uvodi u fibroin svile s biološkim materijalom, i/ili gdje je sredstvo terapijsko sredstvo izabrano iz skupine koja obuhvaća male molekule, lijekove i njihove kombinacije.
A humanized antibody that binds to VLQELNVTV (SEQ ID NO:45) when bound by an HLA-A2 receptor, said antibody comprises a heavy chain variable region consisting of amino acid sequence shown by SEQ ID NO: 16, and a light chain variable region consisting of amino acid sequences shown by SEQ ID NOS: 19 or 20. 
Humanizirano antitijelo koje vezuje VLQELNVTV (SEQ ID NO:45) pri čemu kada se vezuje za HLA-A2 receptor, spomenuto antitijelo obuhvaća varijabilno područje teškog lanca koji se sastoji od aminokiseline koja je prikazana u SEQ ID NO: 16, i varijabilno područje lakog lanca koji se sastoji iz sekvenci aminokiselina koje su prikazane u SEQ ID NOS: 19 ili 20.
An agent for potentiating antitumor effects of a 5-FU antitumor agent comprising the RNAi molecule according to any one of claims 1 to 4 and/or the vector according to claim 5. 
Sredstvo, naznačeno time, da sadrži RNKi-molekulu prema zahtjevu 1 ili zahtjevu 2, i/ili vektor prema zahtjevu 3, te time, da se upotrebljava u postupku medicinskog liječenja.
The compound for use of claim 12, wherein the JAK modulated disease is a JAK2 modulated disease, optionally wherein JAK2 is wild type or mutant JAK2. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je bolest modulirana enzimom JAK bolest modulirana enzimom JAK2, gdje je izborno JAK2 divljeg tipa ili mutantnini JAK2.
The compound or pharmaceutically acceptable salt thereof of claim 7 wherein ArR4R5 is selected from the group consisting of: wherein R9 is selected from H, methyl, and ethyl. 
Spoj za uporabu prema zahtjevu 23, ili njegova farmaceutski prihvatljiva sol, naznačen,a time, da Ar je odabran iz skupine koju čine: fenil, supstituirani fenil, tiofen-il, supstituirani tiofen-il, piridinil, supstituirani piridinil, tiazolil i supstituirani tiazolil.
From the plate-shaped composite structure of Figure 3, an individual arrangement 1 like that shown in the perspective view of Figure 1 is obtained by separating the plate-shaped composite structure by mechanical machining along lines 6, which extend between each two groove structures 4 and which are shown by the dash-dot lines in Figure 3, so that thereafter the block-like nozzle arrangements 1 exist separately. 
Pojedinačna naprava 1, kao ona koja prikazana u perspektivi na slici 1, dobivena je od pločaste kompozitne strukture sa slike 3 odvajanjem pločaste kompozitne strukture mehaničkom strojnom obradom uzduž linija 6, koje se protežu između svake od dviju brazdastih struktura 4 i koje su na slici 3 prikazane crtkanim linijama, tako da nakon toga postoji odvojena naprava 1 s mlaznicom slična bloku.
X' is a second halide anion which is different from the first halide anion; and y is from 0.05 to 2.95; and the process comprises mixing: 
X ' je drugi anion halida koji je različit od prvog halidnog aniona 1 y je od 0, 05 do 2, 95. pod uvjetom da:
Hence, a further object of the present invention is a process for preparing a compound according to formula (1), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, as defined above, comprising reacting a compound according to formula (11), or salt thereof, 
Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli: ovna kato KIS ad gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da obuhvaća rekciju spoja u skladu sa sljedećom formulom (11) ili njegove soli:
The method according to any one of claims 1 to 3, wherein the treatment is performed on Refuse Derived Fuel, in the form of waste bales, by compressed-air injection of the polymer of the superabsorbent polyelectrolytic macromolecular type hydrogel in the dry state, optionally in combination with a component, which is suitable to absorb the gaseous phase produced by the waste, said component being selected from the group that consists of Y-cyclodextrins, zeolites, activated carbons, cellulose derivates, porous ceramics and any combination thereof, within the Refuse Derived Fuel. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time što se obrada provodi na gorivu od predobrađenog otpada, u obliku bala otpada, injektiranjem komprimiranog zraka polimera superapsorbirajućeg polielektrolitičkog makromolekularnog tipa hidrogela u suhom stanju, proizvoljno u kombinaciji s komponentom, koja je prikladna za apsorpciju plinovite faze proizvedene iz otpada, te je navedena komponenta odabrana iz skupine koja sadrži y-ciklodekstrine, zeolite, aktivirani ugljen, derivate celuloze, poroznu keramiku i bilo koje njihove kombinacije, unutar goriva od predobrađenog otpada.
The grip-type locking device as set forth in claim 1, wherein the cable (60) is an integrated type without having an intermediate connecting portion, and passes through the body (10) to be securely coupled thereto. 
Stezna naprava za osiguranje prema patentnom zahtjevu 1, naznačena time da je kabel (60) integriranog tipa bez spojnog dijela između, 1 prolazi kroz tijelo (10) da bi za njega bio čvrsto spojen.
The pharmaceutical composition according to claim 18, wherein the δ-amino-Y-hydroxy-w-aryl-alkanoic acid amide derivative is a compound of formula (I) wherein R1 is 3-methoxypropoxy; R2 is methoxy; and R3 and R4 are isopropyl; or a pharmaceutically acceptable salt thereof. 
Farmaceutski pripravak u skladu sa zahtjevom 18, naznačen time, da derivat amida δ-amino-Y-hidroksi-w-aril-alkanoične kiseline je spoj formule (I) gdje R1 je 3-metoksipropoksi; R2 je metoksi; te R3 i R4 su izopropil; ili je njegova farmaceutski prihvatljiva sol.
The method according to claim 6, wherein the polymerization of the polymerizable resin base is initiated by application of ultrasound. 
Metoda prema jednom od patentnih zahtjeva 11-12, naznačena time da je polimerizacija baze za smolu inicirana primjenom ultrazvuka.
The compound or a pharmaceutically acceptable salt thereof for use according to any of claims 17 to 18, wherein said use is in combination with at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor. 
Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 4 ili 5, naznačen time da je navedeno korištenje u kombinaciji s najmanje jednim sredstvom za poboljšavanje kognitivnih funkcija, sredstvom za pospješivanje pamćenja 1li inhibitorom kolin esteraze.
or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, and wherein 
N ili njegova farmaceutski prihvatljiva sol ili solvat, ili njegov njegov enantiomer ili dijastereomer, te gdje
The kit of any of claims 9-15, wherein the binding agent is provided as a dry powder in a sealed package and the pharmaceutically acceptable excipient provided in a vial or other container. 
Komplet prema bilo kojem od zahtjeva 43-57, naznačen time da je sredstvo za vezanje dobiveno kao suhi prah u zabrtvljenom pakiranju i farmaceutski prihvatljivo pomoćno sredstvo koje je osigurano u epruveti ili drugoj posudi.
A plant according to claim 1, wherein the coolant is propane. 
Postrojenje prema bilo kojem od prethodnih zahtjeva, naznačeno time što je rashladno sredstvo propan.
n is an integer from 3 to 6; and 
n je cijeli broj od 3 do 6; i
The method of paragraph 1, wherein the isolated molecule that selectively binds to ABCB5 is an isolated peptide. 
Izolirano monoklonsko protutijelo koje se selektivno veže na ABCBS5 prema zahtjevu 1, naznačeno time da se izolirano monoklonsko antitijelo veže na ljudski ABCBS5.
The combination for use according to claim 21, wherein the dimethylfumarate is contained in a prolonged release matrix portion of a tablet and the one agent selected from teriflunomide, fingolimod and laquinimod is contained in a coating surrounding the matrix portion. 
Kombinacija za uporabu prema zahtjevu 21., naznačena time što je dimetilfumarat sadržan u dijelu matrice tablete s produljenim oslobađanjem i jedno sredstvo odabrano između teriflunomida, fingolimoda i lakvinimoda sadržano je u ovojnici koja okružuje dio matrice. HR P20180939 T1
The universal and rapid covering system according to claim 1, wherein the cover (1) is fastened to the object to be covered by means of spring clamps. 
Univerzalan 1 brz sustav prekrivanja prema zahtjevu 1, pri čemu je prekrivač (1) vezan za objekt koji se prekriva pomoću kliješta za zatezanje.
The system of claim 3, wherein the conduit of the first electromagnetic applicator is positioned horizontally relatively to the ground. 
Sustav iz patentnog zahtjeva 3, naznačen time, da je cjevovod prvog elektromagnetskog aplikatora postavljen horizontalno u odnosu na tlo.
The process of claim 3 wherein the hydrogen chloride is added as gaseous hydrogen chloride. 
Postupak iz zahtjeva 5 gdje se klorovodik dodaje kao plinoviti klorovodik.
anaerobically digesting the hydrolyzed sludge in the anaerobic digester. 
(h) anaerobne digestije hidroliziranog mulja u anaerobnom digestoru (120).
Use of claim 1, wherein HIV titer in the subject infected with HIV is decreased after contacting the subject with the isolated polypeptide. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time što se HIV titar kod subjekta inficiranog HIV-om smanjuje nakon kontaktiranja subjekta s izoliranim polipeptidom.
The compound of any one of claims 1-11, a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 13 for use in a method for treating disorders related to GABA function in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a compound of one of claims 1-11, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 13, optionally wherein the disorder is selected from the group consisting of insomnia, mood disorders, convulsive disorders, anxiety, or symptoms of ethanol withdrawal. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16 ili farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 17 do 22, naznačeni time što su namijenjeni upotrebi u postupku liječenja poremećaja povezanih s funkcijom GABA kod subjekta kojem je to potrebno, gdje se navedeni postupak sastoji u primjeni na subjektu terapijski djelotvorne količine spoja.
The combination for use as claimed in any one of claims 1 to 5, wherein the ((2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate and the carbonic anhydrase inhibitor are administered topically as one or more eye drops to the eye of the subject. 
Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, pri čemu se ((2R,3S,4R,5R)-5-(6- (ciklopentilamino)-9H-purin-9-11)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrat i inhibitor - karboanhidraze primjenjuju topički kao jedna ili više kapi u oko subjekta.
A safety glove according to claim 8 or 9, wherein said attachment is made of hard plastic. 
Zaštitna rukavica (2) u skladu s patentnim zahtjevom 6 ili 7, naznačena time što je navedeni dodatak (1) načinjen od tvrde plastike.
A process for the preparation of a structured soy bean protein extrudate, comprising the steps of providing an aqueous soy protein composition, wherein the protein content based on dry matter is at least 15% by weight and below 85% by weight; 
Postupak za pripravu strukturiranog ekstrudata proteina zrna soje, koji obuhvaća korake (a) osiguravanje vodenog soja proteinskog sastava, pri čemu je sadržaj proteina baziran na suhoj tvari najmanje 15 tež % i ispod 85 tež. %;
The formulation according to claim 8, wherein the buffer is in a concentration ranging from 1 to 100 mM or from 5 to 50 mM or from 10 to 20 mM. 
Formulacija prema zahtjevu 7, naznačena time da je pufer u koncentraciji u rasponu od 1 do 100 mM ili od 5 do 50 mM ili od 10 do 20 mM.
or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein: 
Gi II ili njegov enantiomer ili smjesa enantiomera ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, kokristal, klatrat ili polimorf, naznačena time, da:
Method for preventing, slowing the progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabetes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, diabetic foot, arteriosclerosis, myocardial infarction, accute coronary syndrome, unstable angina pectoris, stable angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis, in a patient in need thereof characterized in that an SGLT2 inhibitor, a DPP IV inhibitor and a third antidiabetic agent according to claim 1 are administered to the patient. 
prevencija, usporavanje progresije, odgađanje ili liječenje stanja ili poremećaja odabranog iz skupine koja se sastoji od sljedećih: komplikacije dijabetesa mellitus kao što su katarakte i mikro- i makrovaskularne bolesti, primjerice nefropatija, retinopatija, neuropatija, ishemija tkiva, dijabetičko stopalo, arterioskleroza, infarkt miokarda, akutni koronarni sindrom, nestabilna angina pektoris, stabilna angina pektoris, moždani udar, okluzijska bolest perifernih arterija, kardiomiopatija, zatajenje srca, poremećaji srčanog ritma i vaskularna restenoza; ili
The process of clause 57, wherein step (d) comprises treating the compound of formula (VIII) with an acid and isolating the compound of formula (VII) as the acid addition salt. The process of clause 65, wherein the acid is trifluoroacetic acid. 
Postupak prema patentnom zahtjevu 38, gdje korak (d) sadrži tretman spoja formule (VZII) kiselinom (na primjer trifluorooctenom kiselinom) i izolaciju spoja formule (VII) kao kisele adicijske soli.
n represents an integer of 1 to 6; and X2 represents a halogen or a group causing a substitution reaction similar to that of a halogen, with a compound or a salt thereof represented by the general formula (4): wherein R2 represents a pyperidyl group represented by the general formula (A1): (wherein R3 represents: 
(3) u kojoj R' predstavlja vodik ili skupinu niži alkil; n predstavlja cijeli broj od 1 do 6; i X* predstavlja halogen ili skupinu koja uzrokuje reakciju supstitucije poput halogena, sa spojem ili njegovom soli, prikazanim općom formulom (4): u kojoj R* predstavlja piperidinilnu skupinu prikazanu općom formulom (A1):
An isolated nucleic acid encoding a modified relaxin polypeptide chain comprising a non-naturally encoded amino acid, wherein: (a) said isolated nucleic acid comprises a selector codon that encodes said non-naturally encoded amino acid; (b) the encoded modified relaxin polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 containing one non-naturally encoded amino acid substitution; and (c) said non-naturally encoded amino acid occurs at residue 1 of the A chain of SEQ ID NO:4 or the corresponding position of said modified relaxin polypeptide, and said non-naturally encoded amino acid comprises a para-acetyl-L-phenylalanine. 
Metoda proizvodnje modificiranog polipeptida relaksina prema bilo kojem od patentnih zahtjeva 1 do 11, koja sadrži: kultiviranje stanica koje sadrže (1) polinukleotid ili polinukleotide koji kodiraju navedeni polipeptid A lanca relaksina i navedeni polipeptid B lanca relaksina koji sadrži selektor kodon koji kodira navedenu ne-prirodno kodiranu aminokiselinu, (2) ortogonalnu RNK sintetazu i (3) ortogonalnu tRNK pod uvjetima koji dozvoljavaju eksprimiranje polipeptida relaksina koji sadrži navedenu ne-prirodno kodiranu aminokiselinu; i pročišćavanje polipeptida relaksina koji sadrže navedenu ne-prirodno kodiranu aminokiselinu.
The insoluble matter may suitably be solubilised by e.g. sonication or by adding solvent. 
Netopljiva tvar se može prikladno solubilizirati npr. ozvučivanjem ili dodavanjem otapala.
extracting said gas mixture from said pyrolysis chamber; 
ekstrahiranje (150) navedene smjese plinova (30) iz komore za pirolizu (52);
A counter as claimed in claim 2 wherein said coupling mechanism (700) comprises first and second engagement means (704, 705, 1516), said first engagement means being movable radially outwardly and radially inwardly relative to said axis. 
Brojač kao što je navedeno u zahtjevu 2 naznačeno time da navedeni mehanizam sparivanja (700) sadrži prvo 1 drugo sredstvo uključenja (704, 705, 1516), navedeno prvo sredstvo uključenja bivajući pomično radijalno prema van i radijalno prema unutra u odnosu na spomenutu os.
Pharmaceutical Compositions In one embodiment, the present invention is a pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula 
Nevodeni farmaceutski pripravak, koji sadrži: terapijski učinkovitu količinu spoja djelatnog farmaceutskog sastojka (API) koji je predstavljen sljedećom strukturnom formulom najmanje jedno sredstvo za zakiseljavanje; i bazu nosača koja je najmanje jedno farmaceutski prihvatljivo nevodeno otapalo, naznačen time, što nje 5, 6ili 7,
FIG. 5 shows a bottom view of a preferred form of the invention in this view the cap is fitted over the mouthpiece overlying the portion of the mouthpiece which projects form the main body of the inhaler and occluding the opening of the mouthpiece through which the medicament exits the inhaler. 
Slika 5 je pogled odozdo na poželjnu realizaciju ovog izuma kada je zatvarač postavljen preko kljuna tako da okružuje onaj dio kljuna koji strši iz glavnog tijela inhalatora i okružuje otvor kljuna kroz kojega medikament izlazi iz inhalatora.
Then, WFI was drained. 
Nakon toga, WFI je bila ocijeđena.
On cooling the vial was opened and the contents filtered through a Whatman 5 uM filter tube, washing the filter cake with methanol (2×1 mL). 
Nakon hlađenja bočicu se otvori, a sadržaj pročisti kroz 5 uM cijevni Whatmanov filtar, uz ispiranje filtarskog kolača metanolom (2 X 1 ml).
having a tapped density of at least 0.4 g/mL, and/or 
ima prostornu gustoću od barem 0,2 g/ml, ili
coating the digitally printed decor with a overlay at conditions which ensure curing of both the basic layer and the overlay. 
premazivanja digitalno otisnutog dekora pokrovnim slojem (5) pod uvjetima koji osiguravaju umrežavanje i osnovnog sloja i pokrovnog sloja.
The organic partition was evaporated to yield approximately 660mg of crude product. 
Organski dio je bio isparen da bi se dobilo približno 66 mg sirovog produkta.
The method according to claim 1, wherein the oxygen level of the gas exiting the waste treatment apparatus is maintained within the 1-16% range. 
Metoda prema zahtjevu 1 ili 2, naznačena time da se razina kisika u plinu koji izlazi iz uređaja održava unutar raspona od 1-16%.
The present invention thus provides dihydrospiro-[cycloalkylamine]-pyrimidone derivatives represented by formula (I) or salts thereof, solvates thereof or hydrates thereof: wherein: 
Prema tome, ovaj izum osigurava dihidrospiro[cikloalkilamin|pirimidonske derivate, prikazane formulom (1), ili njihove soli, njihove solvate ili hidrate:
A compound of the following formula (1) in crystalline form: 
Natrijeva sol, naznačena time, da je od spoja sljedeće formule (1):
and R2 are independently selected from H, D, halogen, haloalkyl, C1-6 alkyl (optionally substituted with R6), hydroxyl, and alkoxy optionally substituted with R6, and C3-6 cycloalkyl optionally substituted with R6; optionally, when R1 and R2 are attached to the same carbon atom, together they form an oxo group or C3-6 cycloalkyl; optionally, when R1 and R2 are attached to carbon atoms adjacent to each other, together they form a bond or carbocyclyl; optionally, R1 and R15 or R2 and R15 taken together form a ring; 
i R2 su nezavisno odabrani od H, D, halogen, haloalkil, C1-6 alkil (po izboru supstituiran sa R6), hidroksil, i alkoksi po izboru supstituiran sa R6, i C3-6 cikloalkil po izboru supstituiran sa R6; po izboru, kada su R1 i R2 vezani za isti atom ugljika, oni zajedno formiraju okso grupu ili C3-6 cikloalkil; po izboru, kada su R1 i R2 vezani za atome ugljika koji su susjedni jedni drugima, oni zajedno formiraju vezu ili karbociklil; po izboru, R1 i R15 ili R2 i R15 uzeti zajedno formiraju prsten;
A pyridyl-triazolopyrimidine derivative represented by the formula (I) or its salt: wherein 
PATENTNI ZAHTJEVI Piridil-triazolopirimidin derivat predstavljen formulom (1) ili njegove soli,